Back to today’s briefing

Story perspectives

Tariff Pressure and Regulations Threaten Drug Prices and R&D

10/7/2025

26 4 Full Breakdown

Summary

Story summary

A 15% tariff ceiling on most imports, including pharmaceuticals, may push prices higher.
Stricter EU and US regulations raise costs and delay drug development, hindering R&D.
President Donald J. Trump’s Most Favored Nation (MFN) pricing policies prompt pharma firms to reevaluate global pricing, potentially raising prices abroad.
Firms prioritize strategic decisions and flexible agreements to build resilience amid tariff pressure.

History

Historical Context

The Most Favored Nation (MFN) policy, established by the U.S. in 1984, aimed to ensure equal trade advantages among nations, impacting pharmaceutical pricing. This principle, rooted in trade agreements dating back to the 18th century, is now being revisited under President Trump's administration, prompting pharmaceutical companies to reevaluate their global pricing strategies, which could affect consumer costs significantly.

1 of 2

Story summary

A 15% tariff ceiling on most imports, including pharmaceuticals, may push prices higher.
Stricter EU and US regulations raise costs and delay drug development, hindering R&D.
President Donald J. Trump’s Most Favored Nation (MFN) pricing policies prompt pharma firms to reevaluate global pricing, potentially raising prices abroad.
Firms prioritize strategic decisions and flexible agreements to build resilience amid tariff pressure.

1 / 2